Innovent’s Adalimumab And Bevacizumab Get New Indications In China
New Indications Include Treatment of Psoriasis, Uveitis And Glioblastoma
Chinese biotech specialist Innovent Biologics has received approval for new indications for its adalimumab and bevacizumab biosimilars from China’s NMPA.
